Stifel Nicolaus analyst Alex Thompson CFA maintained a Hold rating on Morphic Holding (MORF – Research Report) on October 13 and set a price target of $27.00. The company’s shares closed last Friday at $21.63.
According to TipRanks, Thompson CFA is a 4-star analyst with an average return of 12.8% and a 43.75% success rate. Thompson CFA covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Aeglea Biotherapeutics, and Argenx Se.
Morphic Holding has an analyst consensus of Moderate Buy, with a price target consensus of $64.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $63.08 and a one-year low of $19.80. Currently, Morphic Holding has an average volume of 1.01M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Morphic Holding (MORF) Company Description:
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Read More on MORF:
- Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
- Biotech Alert: Searches spiking for these stocks today
- Morphic price target lowered to $52 from $106 at BMO Capital
- Morphic (NASDAQ:MORF) Resumes Slide After CEO Takes Temporary Leave
- Morphic CEO Dr. Praveen Tipirneni takes leave after ’emergent medical event’
